Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus methotrexate in active rheumatoid arthritis after inadequate response to prior DMARD therapy
2010-020992-21Phase 3Terminated
- Sponsor
- AB Science
- Start
- Jul 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of masitinib and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by AB Science. Primary endpoint: Cumulative response on ACR50. Started Jul 2011; status: terminated.
02
Drugs
masitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-020992-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020992-21.